Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-08-29
2008-09-16
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S023000, C514S062000, C514S154000
Reexamination Certificate
active
07425573
ABSTRACT:
Treating or preventing degeneration or destruction of articular cartilage and/or subchondral bone in the affected joint of a mammal is accomplished by administering a compound of formula (I), wherein the variables have the meanings given in the present description. A preferred compound of formula (I) is formula (II). This treatment ameliorates, diminishes, actively treats, reverses or prevents any injury, damage or loss of articular cartilage or subchondral bone subsequent to said early stage of said degeneration
REFERENCES:
patent: 4232038 (1980-11-01), Kluge et al.
patent: 4704356 (1987-11-01), Thonar
patent: 5095037 (1992-03-01), Iwamitsu et al.
patent: 5260451 (1993-11-01), Dannhardt et al.
patent: 5310759 (1994-05-01), Bockman
patent: 5464609 (1995-11-01), Kelm et al.
patent: 2004/0122002 (2004-06-01), Striegel et al.
patent: 196 24 289 (1998-01-01), None
patent: 196 24 290 (1998-01-01), None
patent: 198 45 446 (2000-04-01), None
patent: 100 01 166 (2001-07-01), None
patent: 100 04 157 (2001-08-01), None
patent: 95 32971 (1995-12-01), None
patent: 95 32972 (1995-12-01), None
patent: 01 05792 (2001-01-01), None
Rabasseda et al., “2-[6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid”, Drugs of the Future, vol. 20, No. 10, pp. 1007-1009.
Abramson SB et al., “Prospects for disease modification in osteoarthritis”, Nat. Clin. Pract. Rheumatol., Jun. 2006; 2(6):304-12, (Abstract only).
Laufer, S. et al. “Acute and Chronic Anti-inflammatory Properites of [2,2-Dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic Acid”, Arzneimittel-Forschung, vol. 45, No. 1, pp. 27-32, XP001109132; ISSN: 0004-4172 1995.
Tries, S. et al. “ML3000, A Novel Anti-Inflammatory Compound without the Potential for Causing Gastric Damage”, Inflammation Research, vol. 50, No. Supplement 3, p. S203, XP008010188, ISSN: 1023-3830 2001.
Tries, S. et al. “Pharmacological Profile of ML3000: A new gastric mucosa sparing anti-inflammatory drug with COX/5-LOX Inhibitory Activity”, Inflammation Research, vol. 50, No. Supplement 3, p. S187, XP008010187, ISSN: 1023-3830 2001.
Gay, Renate E. et al. “Dual Inhibition of 5-Lipoxygenase and Cyclooxygenases 1 and 2 by ML3000 Reduces Joint Destruction in Adjuvant Arthritis”, Journal of Rheumatology, vol. 28, No. 9, pp. 2060-2065, XP008008719, ISSN: 0315-162X 2001.
Laufer, Stefan. “Discovery and Development of ML3000”, Inflammopharmacology, vol. 9, No. 1.2, pp. 101-112, XP008008718, ISSN: 0925-4692 2001.
Dannhardt, Gerd et al. “Aminomethylierung und Arylthiolierung von 6.7-Diaryl-2.3-dihydro-1H-pyrrolizinen”, Arch. Pharm. vol. 319, pp. 65-69 (with English abstract). 1986.
Dannhardt, Gerd et al. “Oxidative Ringoeffnung von 6.7-Diphenyl-2.3-dihydro-1H-pyrrolizin (DADHP) durch m-Chlorperbenzoesaeure”, Arch. Pharm. vol. 319, pp. 231-234 (with English abstract). 1986.
Dannhardt, Gerd et al. “Natriummetaperiodat-Oxidation von 6.7-Diphenyl-2.3-dihydro-1H-pyrrolizin”, Arch. Pharm. vol. 318, pp. 661-663 1985.
Dannhardt, Gerd et al. “6.7-Diaryl-2.3-dihydro-1H-pyrrolizine (DADHP) als Singulett-Sauerstoff-Faenger”, Arch. Pharm. vol. 318, pp. 663-664 1985.
Dannhardt, Gerd et al. “Synthese und Oxidation von 6.7-Diphenyl-2.3-dihydro-1H-pyrrolizin-5-yl-acetaldehyd (DADHP-5-acetaldehyd)”, Arch. Pharm., vol. 319, pp. 500-505 (with English abstract). 1986.
Dannhardt, Gerd et al. “6.7-Diarylsubstituierte 1- und 3-Pyrrolizinone (1-DAPON und 3-DAPON)”, Arch. Pharm. vol. 319, pp. 749-755 (with English abstract). 1986.
Dannhardt, G. et al. “C-5 Functionalized 6,7-Diphenyl-2,3-dihydro-1H-pyrrolizines as Inhibitors of Bovine Cyclooxygenase and 5-Lipoxygenase”, Arch. Pharm. vol. 327, pp. 509-514 1994.
Laufer, Stefan et al. “Synthesis and Evaluation of a Novel Series of Pyrrolizine Derivatives as Dual Cyclooxygenase-1 and 5-Lipoxygenase Inhibitors”, Arch. Pharm. vol. 330, pp. 307-312 1997.
Muchowski, Joseph M. et al. “Synthesis and Antiinflammatory and Analgesic Activity of 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic Acids. The 6-substituted compounds”, J. Med. Chem. vol. 30, pp. 820-823 1987.
Laufer, Stefan A. et al. “(6,7-Diaryldihydropyrrolizin-5-yl)acetic Acids, a Novel Class of Potent Dual Inhibitors of Both Cyclooxygenase and 5-Lipoxygenase”, J. Med. Chem. vol. 37, pp. 1894-1897 1994.
Rabasseda, X. et al. “2-[6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl]acetic acid”, Drugs of the Future, vol. 20, No. 10, pp. 1007-1009 1995.
Fernandes, Julio C. et al. “Effects of Tenidap on Canine Experimental Osteoarthritis”, Arthritis & Rheumatism, vol. 38, No. 9, pp. 1290-1303 1995.
Pelletier, Jean-Pierre et al. “Carprofen Simultaneously Reduces Progression of Morphological Changes in Cartilage and Subchondral Bone in Experimental Dog Osteoarthritis”, The Journal of Rheumatology, vol. 27, No. 12, pp. 2893-2902 2000.
S. Laufer, et al., “Pharmacological Profile of a New Pyrrolizine Derivative Inhibiting the Enzymes Cyclo-oxygenase and 5-Lipoxygenase”, Arzneim-Forsch./Drug Res., vol. 44, No. 1, 1994, 629-636.
Jean-Pierre Pelletier, et al., “Selective Inhibition of Inducible Nitric Oxide Synthase in Experimental Osteoarthritis Is Associated with Reduction in Tissue Levels of Catabolic Factors”, The Journal of Rheumatology, 1999, pp. 2002-2012, 2014 (p. 2013 will be filed later).
Julio C. Fernandez, et al., “The Effects of Tenidap on Canine Experimental Osteoarthritis: II. Study of the Expression of Collagenase-1 and Interleukin 1β by in Situ Hybridization”, The Journal of Rheumatology, 1998, pp. 951-958.
Jean-Pierre Pelletier, et al., “In Vivo Protective Effects of Prophylactic Treatment with Tiaprofenic Acid or Intraarticular Corticosteroids on Osteoarthritic Lesions in the Experimental Dog Model”, Journal of Rheumatology, (Suplemental 27) vol. 18, 1991, pp. 127-130.
Marshall J. Palmoski, et al., “In Vivo Effects of Aspirin on Canine Osteoarthritic Cartilage”, Arthritis and Rheumatism, vol. 26, No. 8, Aug. 1983, pp. 994-1001.
Henry J. Mankin M.D. et al., “Biochemical and Metabolic Abnormalities in Articular Cartilage from Osteo-Arthritic Human Hips”, The Journal of Bone and Joint Surgery, vol. 53-A, No. 3, Apr. 1971, pp. 523-537.
Jean-Pierre Pelletier, et al., “Role of Synovial Membrane Inflammation in Cartilage Matrix Breakdown in the Pond-Nukl Dog Model of Osteoarthritis”, Arthritis and Rheumatism, vol. 28, No. 5, May 1985, pp. 554-561.
Florina Moldovan, et al., “Collagenase-3 (Matrix Metalloprotease 13) Is Preferentially Localized in the Deep Layer of Human Arthritic Cartilage in Situ”, Arthritis and Rheumatism, vol. 40, No. 9, Sep. 1997, pp. 1653-1661.
Edward C. Huskisson, et al., “Effects of Antiinflammatory Drugs on the Progression of Osteoarthritis of the Knee”, The Journal of Rheumatology, pp. 1941-1946, (1995).
Daniel Lajeunesse, et al., Demonstration of an Osteoblast Defect in Two Cases of Human Malignant Osteopetrosis, J. Clin. Invest., The American Society for Clinical Investigation, Inc. vol. 98, No. 8, Oct. 1996, 1835-1842.
Jean-Pierre, et al. “Etiopathogenesis of Osteoarthritis” Arthritis and Allied Conditions: a textbook of rheumatoglogy, 2001, 14thed., pp. 22195-2215.
J. Martel-Pelletier, et al., “Biochemical Factors in Joint Articular Tissue Degradation in Osteoarthritis”, Osteoarthritis: clinical and experimental aspects, 199, pp. 156-187.
Jean-Pierre Pelletier, et al., “Intraarticular injections with Methylprednisolone Acetate Reduce Osteoarthritic Lesions in Parallel With Chondrocyte Stromelysin Synthesis in Experimental osteoarthritis”, Arthritis Rheum, Mar. 1994, 37(3) pp. 414-423.
Martel-Pelletier Johanne
Pelletier Jean-Pierre
Ascentia Pharma Inc.
Henley III Raymond J.
Merckle GmbH
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Use of annellated pyrrole compounds in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of annellated pyrrole compounds in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of annellated pyrrole compounds in the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3992791